{
    "abstractText": "This is an erratum to: Biao Hong, Eryan Yang, Dongyuan Su, Jiasheng Ju, Xiaoteng Cui, Qixue Wang, Fei Tong, Jixing Zhao, Shixue Yang, Chunchao Cheng, Lei Xin, Menglin Xiao, Kaikai Yi, Qi Zhan, Yaqing Ding, Hanyi Xu, Longtao Cui, Chunsheng Kang, EPIC-1042 as a potent PTRF/Cavin1\u2013caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma, Neuro-Oncology, 2023; https://doi.org/10.1093/neuonc/ noad159 In the originally published version of this manuscript, there were errors within the annotations for Figure 5. The TMZ + E (15) figure in green in Panels B, E and G should read: \u201c45\u201d instead of: \u201c15\u201d. In panel G also the IHC of PARP1 of TMZ treatment group was rectified. This does not impact the results.",
    "authors": [
        {
            "affiliations": [],
            "name": "Biao Hong"
        },
        {
            "affiliations": [],
            "name": "Eryan Yang"
        },
        {
            "affiliations": [],
            "name": "Dongyuan Su"
        },
        {
            "affiliations": [],
            "name": "Jiasheng Ju"
        },
        {
            "affiliations": [],
            "name": "Xiaoteng Cui"
        },
        {
            "affiliations": [],
            "name": "Qixue Wang"
        },
        {
            "affiliations": [],
            "name": "Fei Tong"
        },
        {
            "affiliations": [],
            "name": "Jixing Zhao"
        },
        {
            "affiliations": [],
            "name": "Shixue Yang"
        },
        {
            "affiliations": [],
            "name": "Chunchao Cheng"
        },
        {
            "affiliations": [],
            "name": "Lei Xin"
        },
        {
            "affiliations": [],
            "name": "Menglin Xiao"
        },
        {
            "affiliations": [],
            "name": "Kaikai Yi"
        },
        {
            "affiliations": [],
            "name": "Qi Zhan"
        },
        {
            "affiliations": [],
            "name": "Yaqing Ding"
        },
        {
            "affiliations": [],
            "name": "Hanyi Xu"
        },
        {
            "affiliations": [],
            "name": "Longtao Cui"
        },
        {
            "affiliations": [],
            "name": "Chunsheng Kang"
        }
    ],
    "id": "SP:f7291aa56e131e0901a45a65d07dbec236c270f9",
    "references": [],
    "sections": [
        {
            "text": "Neuro-Oncology 25(12), 2306\u20132308, 2023 | https://doi.org/10.1093/neuonc/noad200 | Advance Access date 1 November 2023\nThis is an erratum to: Biao Hong, Eryan Yang, Dongyuan Su, Jiasheng Ju, Xiaoteng Cui, Qixue Wang, Fei Tong, Jixing Zhao, Shixue Yang, Chunchao Cheng, Lei Xin, Menglin Xiao, Kaikai Yi, Qi Zhan, Yaqing Ding, Hanyi Xu, Longtao Cui, Chunsheng Kang, EPIC-1042 as a potent PTRF/Cavin1\u2013caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma, Neuro-Oncology, 2023; https://doi.org/10.1093/neuonc/ noad159 In the originally published version of this manuscript, there were errors within the annotations for Figure 5. The TMZ + E (15) figure in green in Panels B, E and G should read: \u201c45\u201d instead of: \u201c15\u201d. In panel G also the IHC of PARP1 of TMZ treatment group was rectified. This does not impact the results.\n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com\nErratum to: EPIC-1042 as a potent PTRF/Cavin1\u2013 caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma\nD ow nloaded from https://academ ic.oup.com /neuro-oncology/article/25/12/2306/7336862 by Indian Institute of Technology Patna user on 12 January 2024\nN eu roO n colog y 2307Correction\nFigure 5 should read:\nIntracranial\nOral gavage\nDay 0 Day 7 Day 14\nTime (days)\n21\n39.5\n53 57\n62\nKi-67\n\u03b3-H2AX\nPARP1\nDMSO DMSO\n60\n40\nM ed\nia n\nsu rv\niv al\n( da\nys )\nP er\nce nt\no f S\nur vi\nva l\n20\nDM SO TM Z\nTM Z\n+ E\n(1 5)\nTM Z\n+ E\n(3 0)\nTM Z\n+ E\n(4 5)\n\u00d7106\nD ay 7 D ay 1\n4 D ay 2 1\nTMZ\nTMZ\nTMZ + E (15)\nTMZ + E (15)\nTMZ + E (30)\nTMZ + E (30)\nTMZ + E (45)\nTMZ + E (45)\nDMSO TMZ TMZ + E (15) TMZ + E (30) TMZ + E (45)\nDay 21\n1.4\n1.2\n1.0\n0.8\n0.6 0.5\nTMZ (5mg/kg)\nDMSO\nTMZ\nTMZ + E (15) EPIC-1042 treatment\nLu m\nin es\nce nc\ne (\u00d7\n10 6 )\nIVIS\n0 0\nA\nB\nF\nH\nJ K\nI\nG\nE\nC D\n7 14 Time (days)\nTime (days)\n21\n10 0\n50\n100\n20 30 40 50 60 70\n50\n100 150 200\nTMZ + E (15)\nTMZ + E (30)\nTMZ + E (45)\nLu m\nin es\nce nc\ne (\u00d7\n10 6 )\n0 0 7 14\nTime (days) 21\n20\n10\n30\n40 50\nTBD-0220-Luc 1 .105 cells\nIntracranial Oral gavage\nTMZ (5mg/kg) EPIC-1042 (15mg/kg) MRI\nDay 7 Day 14 Day 21 Day 28\n0\nDMSO n.s. EPIC-1042 TMZ TMZ+EPIC\nDMSO n.s. EPIC-1042 TMZ TMZ+EPIC\nT M\nZ +\nE P\nIC T\nM Z\nE P\nIC -1\n04 2\nD M\nS O\nT um\nor v\nol um\ne (m\nm 3 )\n0 P ro\nba bi\nlit y\nof S\nur vi\nva l\n0\n50\n100\n0 7 14 21 28\n20\n40\n60\n80\n7 14 21 28 42 49 Time (days)\nTBD-0220-Luc 1 .105 cells\nTime (days) 0 20 40 60 80\nTime (days)\nD ow nloaded from https://academ ic.oup.com /neuro-oncology/article/25/12/2306/7336862 by Indian Institute of Technology Patna user on 12 January 2024\ninstead of:\nThe emendations have been made in the article. D ow\nnloaded from https://academ ic.oup.com /neuro-oncology/article/25/12/2306/7336862 by Indian Institute of Technology Patna user on 12 January 2024"
        }
    ],
    "year": 2023
}